Developing a new class of anti-cancer therapy for patients with advanced disease

Orally bioavailable small molecule with dual mechanisms of action

Granted Orphan Drug Designation for the treatment of glioma

Latest news

Clinical Trial Application for Phase I trial of AXL1717 new capsule formulation submitted in India

9 January 2018 Since 2015 Axelar AB has had a co-development agreement with Cadila Pharmaceuticals Ltd for … More »

Axelar attends BIO-Europe partnering conference in Berlin, Germany

6 November 2017 Axelar AB will attend the 23rd annual BIO-Europe conference in Berlin, Germany on November 6-8, … More »